Recent news about Johnson & Johnson (JNJ) offers insights into its varied activities and performance. The company's Q2 2025 earnings surpassed estimates, with impressive sales growth despite challenges. It boosted its annual forecast due to a strong performance from cancer drugs and medical devices. The firm also received a U.S FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer. J&J launched the ETHICON™ 4000 Stapler, contributing to surgical innovation. The company also faced legal issues, involving a $42M verdict in an asbestos baby powder case, and a ruling against its rebate model.
Johnson & Johnson had stakes adjusted by several firms, including Nicolet Advisory Services, Howland, First National Trust Co, and Eastern Bank. Furthermore, it was added to Fortune’s 2025 America’s Most Innovative Companies list and received an upgrade to 'Buy' from analysts as growth and margins impress.
J&J is working on varied health initiatives, from cancer treatments to food security. However, the company also faces backlash over alleged unlawful DEI policies across its operations. Despite hurdles, Johnson & Johnson displays consistent performance making it a recommended long-term momentum stock.
Johnson Johnson JNJ News Analytics from Tue, 15 Oct 2024 07:00:00 GMT to Sat, 02 Aug 2025 13:01:49 GMT - Rating 4 - Innovation 7 - Information 6 - Rumor 2
